Impact of Preoperative CEA Uptrend on Survival Outcomes in Patients with Colorectal Liver Metastasis After Hepatectomy.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
13
12
2021
accepted:
16
05
2022
pubmed:
13
6
2022
medline:
24
9
2022
entrez:
12
6
2022
Statut:
ppublish
Résumé
Preoperative carcinoembryonic antigen (CEA) has been reported as a prognostic factor in patients with colorectal liver metastasis (CRLM) after hepatectomy. However, the impact of a preoperative "CEA uptrend" on prognosis after hepatectomy in these patients remains unknown. This study assessed the impact of CEA uptrend on prognosis in patients undergoing hepatectomy for CRLM. Consecutive patients with CRLM who underwent hepatectomy between 2009 and 2018 were retrospectively analyzed. Patients with CRLM for whom CEA was measured both around 1 month before (CEA-1m) and within 3 days (CEA-3d) before hepatectomy were enrolled. A CEA-3d higher than both the upper limit of normal (5 ng/ml) and CEA-1m was defined as a CEA uptrend. Study participants comprised 212 patients with CRLM. Of these, 88 patients (41.5%) showed a CEA uptrend. CEA uptrend indicated better discriminatory ability (corrected Akaike information criteria, 733.72) and homogeneity (likelihood ratio chi-square value, 18.80) than CEA-3d or CEA-1m. Patients with CEA uptrend showed poorer overall survival than those without CEA uptrend (p < 0.001). After adjusting for known prognostic factors, the prognostic significance of CEA uptrend retained (hazard ratio 2.63, 95% confidence interval 1.63-4.26, p < 0.001). In subgroup analyses, the prognostic significance of CEA uptrend was retained irrespective of the status of RAS mutation or response to preoperative chemotherapy. CEA uptrend offers better prediction of survival outcomes than conventional CEA measurements in patients undergoing hepatectomy for CRLM.
Sections du résumé
BACKGROUND
BACKGROUND
Preoperative carcinoembryonic antigen (CEA) has been reported as a prognostic factor in patients with colorectal liver metastasis (CRLM) after hepatectomy. However, the impact of a preoperative "CEA uptrend" on prognosis after hepatectomy in these patients remains unknown. This study assessed the impact of CEA uptrend on prognosis in patients undergoing hepatectomy for CRLM.
METHODS
METHODS
Consecutive patients with CRLM who underwent hepatectomy between 2009 and 2018 were retrospectively analyzed. Patients with CRLM for whom CEA was measured both around 1 month before (CEA-1m) and within 3 days (CEA-3d) before hepatectomy were enrolled. A CEA-3d higher than both the upper limit of normal (5 ng/ml) and CEA-1m was defined as a CEA uptrend.
RESULTS
RESULTS
Study participants comprised 212 patients with CRLM. Of these, 88 patients (41.5%) showed a CEA uptrend. CEA uptrend indicated better discriminatory ability (corrected Akaike information criteria, 733.72) and homogeneity (likelihood ratio chi-square value, 18.80) than CEA-3d or CEA-1m. Patients with CEA uptrend showed poorer overall survival than those without CEA uptrend (p < 0.001). After adjusting for known prognostic factors, the prognostic significance of CEA uptrend retained (hazard ratio 2.63, 95% confidence interval 1.63-4.26, p < 0.001). In subgroup analyses, the prognostic significance of CEA uptrend was retained irrespective of the status of RAS mutation or response to preoperative chemotherapy.
CONCLUSIONS
CONCLUSIONS
CEA uptrend offers better prediction of survival outcomes than conventional CEA measurements in patients undergoing hepatectomy for CRLM.
Identifiants
pubmed: 35691953
doi: 10.1245/s10434-022-11973-8
pii: 10.1245/s10434-022-11973-8
doi:
Substances chimiques
Carcinoembryonic Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6745-6754Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. Society of Surgical Oncology.
Références
Brennaer H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490–502.
doi: 10.1016/S0140-6736(13)61649-9
Engstrand J, Nilsson H, Strömberg C, et al. Colorectal cancer liver metastases: A population-based study on incidence, management and survival. BMC Cancer. 2018;18(1):78. https://doi.org/10.1186/s12885-017-3925-x .
doi: 10.1186/s12885-017-3925-x
pubmed: 29334918
pmcid: 5769309
House MG, Ito H, Gonen M, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010;210(5):744–52.
doi: 10.1016/j.jamcollsurg.2009.12.040
Sakamoto K, Honda G, Beppu T, et al. Comprehensive data of 3,820 patients newly diagnosed with colorectal liver metastasis between 2005 and 2007: report of a nationwide survey in Japan. J Hepatobiliary Pancreat Sci. 2018;25(2):115–23.
doi: 10.1002/jhbp.510
Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313–27.
doi: 10.1200/JCO.2006.08.2644
Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(6):64–72.
doi: 10.1093/annonc/mdt354
Duffy MJ, Lamerz R, Haglund C, et al. Tumor makers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer. 2014;134(11):2513–22.
doi: 10.1002/ijc.28384
Araujo RL, Gönen M, Allen P, et al. Positive postoperative CEA is a strong predictor of recurrence for patients after resection for colorectal liver metastases. Ann Surg Oncol. 2015;22(9):3087–93. https://doi.org/10.1245/s10434-014-4358-2 .
doi: 10.1245/s10434-014-4358-2
pubmed: 25582745
pmcid: 4526451
Neofytou K, Giakoustidis A, Neves MC, et al. Increased carcinoembryonic antigen (CEA) following neoadjuvant chemotherapy predicts poor prognosis in patients that undergo hepatectomy for liver-only colorectal metastases. Langenbecks Arch Surg. 2017;402(4):599–605.
doi: 10.1007/s00423-016-1415-2
John SK, Robinson SM, Rehman S, et al. Prognostic factors and survival after resection of colorectal liver metastasis in the era of preoperative chemotherapy: an 11-year single-centre study. Dig Surg. 2013;30(4–6):293–301.
doi: 10.1159/000354310
Sakamoto Y, Miyamoto Y, Beppu T, et al. Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy. Anticancer Res. 2015;35(4):2359–68.
pubmed: 25862901
Okazaki S, Baba H, Iwata N, et al. Carcinoembryonic antigen testing after curative liver resection for synchronous liver metastasis of colorectal cancer: a Japanese multicenter analysis. Surg Today. 2017;47(10):1223–9.
doi: 10.1007/s00595-017-1530-x
Bredt LC, Rachid AF. Predictors of recurrence after a first hepatectomy for colorectal cancer liver metastases: a retrospective analysis. World J Surg Oncol. 2014. https://doi.org/10.1186/1477-7819-12-391 .
doi: 10.1186/1477-7819-12-391
pubmed: 25528650
pmcid: 4364583
Nagai Y, Beppu T, Sakamoto Y, et al. Carcinoembryonic antigen half-life is an early predictor of therapeutic effects in induction chemotherapy for liver metastases from colorectal cancer. Anticancer Res. 2014;34(10):5529–35.
pubmed: 25275051
Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258(4):619–26.
doi: 10.1097/SLA.0b013e3182a5025a
Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2015;486(7404):532–6.
doi: 10.1038/nature11156
Gagnière J, Dupré A, Gholami SS, et al. Is hepatectomy justified for BRAF mutant colorectal lover metastases?: A multi-institutional analysis of 1497 patients. Ann Surg. 2020;271(1):147–54.
doi: 10.1097/SLA.0000000000002968
Liu W, Zhang W, Xu Y, et al. A prognostic scoring system to predict survival outcome of resectable colorectal liver metastases in this modern era. Ann Surg Oncol. 2021;28(12):7709–18. https://doi.org/10.1245/s10434-021-10143-6 .
doi: 10.1245/s10434-021-10143-6
pubmed: 34023948
Okuno M, Goumard C, Kopetz S, et al. RAS mutation is associated with unsalvageable recurrence following hepatectomy for colorectal cancer liver metastases. Ann Surg Oncol. 2018;25(8):2457–66. https://doi.org/10.1245/s10434-018-6517-3 .
doi: 10.1245/s10434-018-6517-3
pubmed: 29786130
Tsilimigras DI, Ntanasis-Stathopoulos I, Bagante F, et al. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: a systematic review of the current evidence. Surg Oncol. 2018;27(2):280–8.
doi: 10.1016/j.suronc.2018.05.012
Gau L, Ribeiro M, Pereira B, et al. Impact of BRAF mutations on clinical outcomes following liver surgery for colorectal liver metastases: an updated meta-analysis. Eur J Surg Oncol. 2021. https://doi.org/10.1016/j.ejso.2021.05.039 .
doi: 10.1016/j.ejso.2021.05.039
pubmed: 34099355
Dijkstra M, Nieuwenhuizen S, Puijk RS, et al. Primary tumor sidedness, RAS and BRAF mutations and MSI status as prognostic factors in patients with colorectal liver metastases treated with surgery and thermal ablation: results from the Amsterdam Colorectal Liver Met Registry (AmCORE). Biomedicines. 2021;9(8): https://doi.org/10.3390/biomedicines9080962
Wanebo HJ, Rao B, Pinsky CM, et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med. 1978;299(9):448–51.
doi: 10.1056/NEJM197808312990904
Clinical practice guidelines for the use of tumor makers in breast and colorectal cancer. Adopted on May, 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol. 1996;14(10):2843-77.
Weiser MR. AJCC 8
doi: 10.1245/s10434-018-6462-1
pubmed: 29616422
Clavien PA, Barkun J, Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–96.
doi: 10.1097/SLA.0b013e3181b13ca2
Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1–42.
doi: 10.1007/s10147-019-01485-z
Couinald C. The anatomy of the liver. Ann Ital Chir. 1992;63(6):693–7.
Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika. 1965;52:203–23.
doi: 10.1093/biomet/52.1-2.203
Yoh T, Seo S, Hatano E, et al. A novel biomarker-based preoperative prognostic grading system for predicting survival after surgery for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2017;24(5):1351–7. https://doi.org/10.1245/s10434-016-5708-z .
doi: 10.1245/s10434-016-5708-z
pubmed: 28108828
Yoh T, Seo S, Ogiso S, et al. Proposal of a New Preoperative Prognostic Model for Solitary Hepatocellular Carcinoma Incorporating
doi: 10.1245/s10434-017-6262-z
pubmed: 29168098
Yamamoto H, Murata K, Fukunaga M, et al. Micrometastasis volume in lymph nodes determines disease recurrence rate of stage II colorectal cancer: a prospective multicenter trial. Clin Cancer Res. 2016;22(13):3201–8.
doi: 10.1158/1078-0432.CCR-15-2199
Huang SC, Lin JK, Lin TC, et al. Concordance of carcinoembryonic antigen ratio and response evaluation criteria in solid tumors as prognostic surrogate indicators of metastatic colorectal cancer patients treated with chemotherapy. Ann Surg Oncol. 2015;22(7):2262–8. https://doi.org/10.1245/s10434-014-4228-y .
doi: 10.1245/s10434-014-4228-y
pubmed: 25586242
Saito G, Sadahiro S, Okada K, et al. Relation between carcinoembryonic antigen levels in colon cancer tissue and serum carcinoembryonic antigen levels at initial surgery and recurrence. Oncology. 2016;91(2):85–9.
doi: 10.1159/000447062
Pilati P, Mocellin S, Bertazza L, et al. Prognostic value of putative circulating cancer stem cells in patients undergoing hepatic resection for colorectal liver metastasis. Ann Surg Oncol. 2012;19(2):402–8. https://doi.org/10.1245/s10434-011-2132-2 .
doi: 10.1245/s10434-011-2132-2
pubmed: 22071867
Hatano E, Okuno M, Nakamura K, et al. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study). J Hepatobiliary Pancreat Sci. 2015;22(8):634–45.
doi: 10.1002/jhbp.254
Okuno M, Hatano E, Toda R, et al. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-RAS status for unresectable colorectal liver metastasis (BECK study): long-term results of survival. J Hepatobiliary Pancreat Sci. 2020;27(8):496–509.
doi: 10.1002/jhbp.747
Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liber lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size setting. Ann Surg. 2012;255(3):405–14.
doi: 10.1097/SLA.0b013e31824856f5
Tsilimigras DI, Ntanasis-Stathopoulos I, Bagante F, et al. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastasis: A systematic review of the current evidence. Surg Oncol. 2018;27(2):280–8.
doi: 10.1016/j.suronc.2018.05.012
Kawaguchi Y, Kopetz S, Newhook TE, et al. Mutation status of RAS, TP53, and SMAD4 is superior to mutation status of RAS alone for predicting prognosis after resection of colorectal liver metastases. Clin Cancer Res. 2019;25(19):5843–51.
doi: 10.1158/1078-0432.CCR-19-0863
Mizuno T, Cloyd JM, Vicente D, et al. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases. Eur J Surg Oncol. 2018;44(5):684–92.
doi: 10.1016/j.ejso.2018.02.247